BofA analyst Michael Ryskin raised the firm’s price target on Phibro Animal Health (PAHC) to $27 from $19 and keeps an Underperform rating on the shares. The firm increased EPS estimates based on the company’s initial FY26 guidance that came in “well ahead” of Street consensus and raised the multiple to reflect the stronger performance, but continues to believe that growth will soon moderate and return to historical levels with limited operating leverage once M&A is annualized, the analyst tells investors.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PAHC:
- Phibro Animal Health Reports Strong Fiscal Year Results
- Phibro Animal Health: Strong Q4 Results and Strategic Growth Initiatives Tempered by Valuation Concerns Leading to Hold Rating
- Phibro Animal Health price target raised to $34 from $26 at Morgan Stanley
- Phibro Animal Health: Strong Q4 Performance Overshadowed by Growth and Profitability Challenges
- Phibro Animal Health sees FY26 EPS $2.52-$2.70, consensus $2.32